>POON Chiu Yee, Liona

POON Chiu Yee, Liona

POON Chiu Yee, Liona

Current Position:
Associate Professor (Clinical)

Office Phone:
(852) 3505 2582

Email:
liona.poon@cuhk.edu.hk

 

Biographical details
Liona Poon was awarded MBBS from University of London in 2002 and undertook her specialty training in Obstetrics and Gynaecology in London. She gained a 3-year training fellowship from the Fetal Medicine Foundation and during this time, established a major screening programme for early detection of preeclampsia, which led to a Doctorate of Medicine (Research) in 2011. She then undertook subspecialty training in maternal fetal medicine at Imperial College Healthcare NHS Trust and King’s College Hospital NHS Foundation Trust with Mr TG Teoh and Professor KH Nicolaides as supervisors.

Qualifications:
MBBS (University of London), MRCOG, MD(Res) (University of London), Cert RCOG (Maternal and Fetal Medicine)

Research interests:
Her main research interests are in the prediction and prevention of maternal and perinatal morbidity and mortality. These include developing screening models for the prediction of aneuploidies, preeclampsia, fetal growth restriction, gestational diabetes, macrosomia, stillbirth, spontaneous preterm birth and induced labour. She is currently conducting a pan-European multicentre randomised controlled trial of Aspirin vs. placebo in the prevention of preterm preeclampsia (ASPRE), which is funded by the EC FP7 scheme. She has authored over 100 peer-reviewed publications in the top quartile of international journals in the field of Obstetrics and Gynaecology and Hypertension.

Grants:
EC FP7 (601852-2), NIHR EME (14/01/02), NIHR HTA (14/158), CUHK Start-up Support Fund, HK O&G Trust Fund

 

1Study protocol for the randomised controlled trial: combined multimarker screening and randomised patient treatment with ASpirin for evidence-based PREeclampsia prevention (ASPRE).
O'Gorman N, Wright D, Rolnik DL, Nicolaides KH, Poon LC
BMJ Open. 2016 Jun 28;6(6):e011801. doi: 10.1136/bmjopen-2016-011801.
2Protocol for the prospective validation study: 'Screening programme for pre-eclampsia' (SPREE)
Tan MY, Koutoulas L, Wright D, Nicolaides KH, Poon LCY
Ultrasound Obstet Gynecol. 2017 Aug;50(2):175-179
3Metabolomic determination of pathogenesis of late-onset preeclampsia
Bahado-Singh RO, Syngelaki A, Mandal R, Graham SF, Akolekar R, Han B, Bjondahl TC, Dong E, Bauer S, Alpay-Savasan Z, Turkoglu O, Ogunyemi D, Poon LC, Wishart DS, Nicolaides KH
J Matern Fetal Neonatal Med. 2017 Mar;30(6):658-664
4Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia
Rolnik DL, Wright D, Poon LC, O'Gorman N, Syngelaki A, de Paco Matallana C, Akolekar R, Cicero S, Janga D, Singh M, Molina FS, Persico N, Jani JC, Plasencia W, Papaioannou G, Tenenbaum-Gavish K, Meiri H, Gizurarson S, Maclagan K, Nicolaides KH
N Engl J Med. 2017 Aug 17;377(7):613-622
5Accuracy of competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 11–13 weeks' gestation
O'Gorman N, Wright D, Poon LC, Rolnik DL, Syngelaki A, Wright A, Akolekar R, Cicero S, Janga D, Jani J, Molina F S, Paco Matallana C, Papantoniou N, Persico N, Plasencia W, Singh M, Nicolaides K H
Ultrasound Obstet Gynecol 2017 Jun;49(6):751-755
6Maternal cardiac function at 35-37 weeks' gestation: relationship with birth weight
Guy G.P., Ling H.Z., Machuca M., Poon LCY, Nicolaides K.H.
Ultrasound Obstet Gynecol. 2017 Jan;49(1):67-72
7Maternal cardiac function at 35-37 weeks’ gestation: prediction of preeclampsia and gestational hypertension
Guy GP, Ling HZ, Garcia P, Poon LCY, Nicolaides KH
Ultrasound in Obstetrics and Gynecology Jan 2017;49(1):61-66
8Maternal Cardiovascular Function at 35-37 Weeks' Gestation: Relation to Maternal Characteristics
Guy GP, Ling HZ, Garcia P, Poon LCY, Nicolaides KH
Ultrasound in Obstetrics and Gynecology Jan 2017;49(1):39-45
9Birth weight in live births and stillbirths
Poon LCY, Tan MY, Yerlikaya G, Syngelaki A, Nicolaides KH
Ultrasound Obstet Gynecol Nov 2016;48(5):602-606
10Metabolomic Determination of Pathogenesis of Late-onset Preeclampsia.
Bahado-Singh RO, Syngelaki A, Mandal R, Akolekar R, Han B, Bjondahl TC, Dong E, Bauer S, Alpay-Savasan Z, Graham S, Turkoglu O, Ogunyemi D, Poon LC, Wishart DS, Nicolaides KH.
Journal of Maternal Fetal and Neonatal Medicine 2016, J Matern Fetal Neonatal Med. 2016; 28: 1-7.
11Study protocol for the randomised controlled trial: combined multimarker screening and randomised patient treatment with ASpirin for evidence-based PREeclampsia prevention (ASPRE).
O'Gorman N, Wright D, Rolnik DL, Nicolaides KH, Poon LC.
BMJ Open 2016; 6:e011801. doi: 10.1136/bmjopen-2016-011801.
12Risk of preterm birth following treatment for cervical disease: Stakeholder meeting summary.
Sasieni P, Castanon A, Landy R, Kyrgiou M, Kitchener H, Quigley M, Poon LC, Shennan A, Paraskevaidis E, Hollingworth A, Soutter P, Freeman Wang T, Peebles D, Prendeville W, Patnick J.
British J Obstet Gynaecol 2015; doi: 10.1111/1471-0528.13839.
13Cervical Cerclage for Preterm Birth Prevention in Twin Gestations with Short Cervix: A Case-Control_ Study.
Houlihan C, Poon LC, Ciarlo M, Kim E, Guzman ER, Nicolaides KH.
Ultrasound Obstet Gynecol 2016, doi: 10.1002/uog.15918.
14Cervical pessary for prevention of preterm birth in singleton pregnancies with short cervical length: a multicentre, randomized controlled trial.
Nicolaides KH, Syngelaki A, Poon LC, Picciarelli G, Tul N, Zamprakou A, Skyfta E, Parra-Cordero M, Palma-Dias R, Rodriquez Calvo J.
New England Journal of Medicine 2016; 374:1044-52.
15Contingent Screening for Small by Weight for Gestational Age Neonates.
Frick AP, Nicolaides KH, Poon LC.
Pediatr Endocrinol Rev 2016;13:568-573.
16The use of ultrasound and other markers for early detection of preeclampsia.
O'Gorman N, Nicolaides KH, Poon LC.
Womens Health (Lond Engl) 2016;12:199-207.
17Clinical implementation of routine screening for fetal trisomies by the cell-free DNA test contingent on results from first-trimester combined test.
Gil MM, Revello R, Poon LC, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2016; 47:45-52.
18Prediction of large for gestational age neonates: Screening by maternal factors and biomarkers in the three trimesters of pregnancy.
Frick A, Syngelaki S, Zheng MM, Poon LC*, Nicolaides KH.
Ultrasound in Obstet Gynecol 2016;47:332-339.
19Current controversies in prenatal diagnosis 3: Is there still a Value in a Nuchal Translucency Screening Ultrasound in conjunction with Maternal Plasma Non-Invasive cell free DNA testing?’
Wilson RD, Poon LC, and Ghidini A.
Prenatal Diagnosis 2015; doi: 10.1002/pd.4719. [Epub ahead of print_]
20First trimester prediction of HELLP Syndrome.
Oliveira N, Poon LC, Nicolaides KH, Baschat AA.
Prenatal diagnosis 2016; 36:29-33.
21Clinical validation of the IONA® test for first-trimester detection of trisomy 21, 18 and 13.
Poon LC, Dumidrascu-Diris D, Francisco C, Fantasia I, Nicolaides KH.
Ultrasound Obstet Gynecol 2016; 47:184-187
22Cervical pessaries for prevention of preterm birth: a randomised controlled trial.
Nicolaides KH, Syngelaki A, Poon LC, De Paco C, Plasencia W, Molina F, Picciarelli G, Tul N, Celik E, Lau TK, Conturso R.
Am J Obstet Gynecol 2016, 214:3.e1-9
23The prediction of preterm birth in twin pregnancy: an individual patient level meta-analysis.
Kindinger LM, Poon LC, Cacciatore S, MacIntyre, Fox NS, Schuit E, Mol B, Liem S, Lim A, Hermans F, Serra V, Perales A, Darzi A, Bennett P, Nicolaides KH, Teoh TG.
British J Obstet Gynaecol 2016; 123:877-884.
24Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks’ gestation.
O’Gorman N, Wright D, Syngelaki A, Akolekar R, Wright A, Poon LC, Nicolaides KH.
Am J Obstet Gynecol 2015, pii: S0002-9378(15)00900-X. doi: 10.1016/j.ajog.2015.08.034. [Epub ahead of print_]
25Prediction of small for gestational age neonates: screening by biophysical and biochemical markers at 19-24 weeks.
Poon LC, Lesmes C, Gallo DM, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol. 2015 May 18. doi: 10.1002/uog.14904. [Epub ahead of print_]
26Poon L. Re: Prediction of early- and late-onset pregnancy-induced hypertension using placental volume on three-dimensional ultrasound and uterine artery Doppler.
T. Arakaki, J. Hasegawa, M. Nakamura, S. Hamada, M. Muramoto, H. Takita, K. Ichizuka and A. Sekizawa. Ultrasound Obstet Gynecol 2015; 45: 539-543.
Ultrasound Obstet Gynecol 2015;45:513.
27Prediction of small for gestational age neonates: Screening by maternal serum biochemical markers at 19-24 weeks.
Lesmes C, Gallo DM, Gonzalez R, Poon LC*, Nicolaides KH.
Ultrasound Obstet Gynecol. 2015 May 13. doi: 10.1002/uog.14899. [Epub ahead of print_]
28Prediction of small-for-gestational-age neonates: maternal biochemical markers at 30-34 weeks.
Bakalis S, Gallo DM, Mendez O, Poon LC*, Nicolaides KH.
Ultrasound Obstet Gynecol 2015; 46: 208-215.
29Prediction of small-for-gestational-age neonates: screening by biophysical and biochemical markers at 30-34 weeks.
Bakalis S, Peeva G, Gonzalez R, Poon LC*, Nicolaides KH.
Ultrasound Obstet Gynecol. 2015 Mar 31. doi: 10.1002/uog.14863. [Epub ahead of print_]
30Prediction of small-for-gestational-age neonates: screening by placental growth factor and soluble fms-like tyrosine kinase-1 at 35-37 weeks.
Fadigas C, Peeva G, Mendez O, Poon LC*, Nicolaides KH.
Ultrasound Obstet Gynecol 2015; 46: 191-197.
31Prediction of small for gestational age neonates: screening by uterine artery Doppler and mean arterial pressure at 19-24 weeks.
Lesmes C, Gallo DM, Saiid Y, Poon LC*, Nicolaides KH.
Ultrasound Obstet Gynecol. 2015 Mar 24. doi: 10.1002/uog.14855. [Epub ahead of print_]
32Prediction of small-for-gestational-age neonates: screening by uterine artery Doppler and mean arterial pressure at 35-37 weeks.
Fadigas C, Guerra L, Garcia-Tizon Larroca S, Poon LC*, Nicolaides KH.
Ultrasound Obstet Gynecol 2015; 45: 715-721.
33Umbilical and fetal middle cerebral artery Doppler at 35-37 weeks' gestation in the prediction of adverse perinatal outcome.
Akolekar R, Syngelaki A, Gallo DM, Poon LC, Nicolaides KH.
Ultrasound Obstet Gynecol 2015; 46: 82-92.
34Prediction of small-for-gestational-age neonates: screening by fetal biometry at 35-37 weeks.
Fadigas C, Saiid Y, Gonzalez R, Poon LC*, Nicolaides KH.
Ultrasound Obstet Gynecol 2015; 45: 559-565.
35Competing risks model in screening for preeclampsia by maternal characteristics and medical history.
Wright D, Syngelaki A, Akolekar R, Poon LC, Nicolaides KH.
Am J Obstet Gynecol 2015; 213: 62.e1-62.e10.
36Prediction of small for gestational age neonates: screening by fetal biometry at 19-24 weeks.
Lesmes C, Gallo D, Panaiotova J, Poon LC*, Nicolaides KH.
Ultrasound Obstet Gynecol 2015; 46: 198-207.
37Umbilical and fetal middle cerebral artery Doppler at 30-34 weeks' gestation in the prediction of adverse perinatal outcome.
Bakalis S, Akolekar R, Gallo DM, Poon LC*, Nicolaides KH.
Ultrasound Obstet Gynecol 2015; 45: 409-420.
38Prediction of small for gestational age neonates: Screening by uterine artery Doppler and mean arterial pressure at 30-34 weeks.
Bakalis S, Stoilov B, Akolekar R, Poon LC*, Nicolaides KH.
Ultrasound Obstet Gynecol 2015; 45: 707-714.
39Mean arterial pressure in the three trimesters of pregnancy: effects of maternal characteristics and medical history.
Wright A, Wright D, Ispas CA, Poon LC, Nicolaides KH.
Ultrasound Obstet Gynecol 2015; 45: 698-706.
40Prediction of small for gestational age neonates: screening by fetal biometry at 30-34 weeks.
Bakalis S, Silva M, Akolekar R, Poon LC*, Nicolaides KH.
Ultrasound Obstet Gynecol 2015; 45: 551-558.
41UK NHS pilot study on cell-free DNA testing in screening for fetal trisomies: Factors affecting uptake.
Gil MM, Giunta G, Macalli EA, Poon LC, Nicolaides KH.
Ultrasound Obstet Gynecol 2015; 45: 67-73.
42Fetal fraction in maternal plasma cell-free DNA in the prediction of spontaneous preterm delivery.
Quezada MS, Francisco C, Dumitrascu-Biris D, Nicolaides KH, Poon LC*.
Ultrasound Obstet Gynecol 2015; 45: 101-105.
43Maternal plasma cell-free DNA in the prediction of preeclampsia.
Rolnik DL, O’Gorman N, Fiolna M, van den Boom D, Nicolaides KH, Poon LC*.
Ultrasound Obstet Gynecol 2015; 45: 106-111.
44Early prediction of preeclampsia.
Poon LC, Nicolaides KH.
Obstet Gynecol Int. 2014; 2014: 297397.
45Management of hypertriglyceridaemia-induced acute pancreatitis in pregnancy.
Amin T, Poon L, Teoh T, Moorthy K, Robinson S.
J Matern Fetal Neonatal Med. 2014 Jul 29:1-13. [Epub ahead of print_]
46Maternal serum anti-Müllerian hormone at 11-13 weeks' gestation in the prediction of preeclampsia.
Birdir C, Fryze J, Vasiliadis H, Nicolaides KH, Poon LC*.
J Matern Fetal Neonatal Med 2015; 28: 954-958.
47Competing risk model in screening for preeclampsia by mean arterial pressure and uterine artery pulsatility index at 30-33 weeks' gestation.
Tayyar A, Garcia-Tizon Larroca S, Poon LC, Wright D, Nicolaides KH.
Fetal Diagn Ther. 2014; 36: 18-27.
48Demographic factors that can be used to predict early-onset pre-eclampsia.
Leung C, Saaid R, Pedersen L, Park F, Poon L, Hyett J.
J Matern Fetal Neonatal Med 2015; 28: 535-539.
49First-trimester maternal factors and biomarker screening for preeclampsia.
Poon LC, Nicolaides KH.
Prenat Diagn 2014; 34: 618-627.
50Successful induction of labor: prediction by pre-induction cervical length, angle of progression and cervical elastography.
Pereira S, Frick AP, Poon LC, Zamprakou A, Nicolaides KH.
Ultrasound Obstet Gynecol 2014; 44: 468-475.
51Is High Fetal Nuchal Translucency Associated with Submicroscopic Chromosomal Abnormalities by Array CGH?
Huang J, Poon LC, Akolekar R, Choy KW, Leung TY, Nicolaides KH.
Ultrasound Obstet Gynecol 2014; 43: 620-624.
52Competing risks model in screening for preeclampsia by biophysical and biochemical markers at 30-33 weeks’ gestation.
Garcia-Tizon Larroca S, Tayyar A, Poon LC, Wright D, Nicolaides KH.
Fetal Diagn Ther 2014; 36: 9-17.
53Prediction of preeclampsia by mean arterial pressure at 11-13 and 20-24 weeks’ gestation.
Gallo D, Poon LC, Fernandez M, Wright D, Nicolaides KH.
Fetal Diagn Ther 2014; 36: 28-37.
54Competing risks model in screening for preeclampsia by serum placental growth factor and soluble fms-like tyrosine kinase-1 at 30-33 weeks’ gestation.
Lai J, Garcia-Tizon Larroca S, Peeva G, Poon LC, Wright D, Nicolaides KH.
Fetal Diagn Ther 2014; 35: 240-248.
55Optimal method and timing of intrauterine intervention in TRAP sequence: case study and meta-analysis.
Chaveeva P, Poon LC, Sotiriadis A, Kosinski P, Nicolaides KH.
Fetal Diagn Ther 2014; 35: 267-279.
56Maternal serum placental growth factor (PlGF) isoforms 1 and 2 at 11-13, 20-24 and 30-34 weeks’ gestation in late onset preeclampsia and small for gestational age.
Nucci M, Poon LC, Demirdjian G, Darbouret B, Nicolaides KH.
Fetal Diagn Ther 2014; 35: 249-257.
57Nucci M, Poon LC, Demirdjian G, Darbouret B, Nicolaides KH.
Maternal serum placental growth factor (PlGF) isoforms 1 and 2 at 11-13 weeks’ gestation in preeclampsia and small for gestational age.
Fetal Diagn Therr 2014; 35: 249-257.
58Prediction of preeclampsia by uterine artery Doppler at 20-24 weeks’ gestation.
Gallo D, Poon LC, Akolekar R, Syngelaki A, Nicolaides KH.
Fetal Diagn Ther 2013; 1: 241-247.
59Trichorionic and dichorionic triplet pregnancies at 10-14 weeks: Outcome after embryo reduction compared to expectant management.
Chaveeva P, Kosinski P, Puglia D, Poon L, Nicolaides K.
Fetal Diagn Ther 2013; 1: 199-205.
60First-trimester contingent screening for trisomies 21, 18 and 13 by biomarkers and maternal blood cell-free DNA testing.
Nicolaides KH, Syngelaki A, Poon LC, Gil M, Wright D.
Fetal Diagn Ther 2014; 35: 185-192.
61Clinical evaluation of a first trimester algorithm predicting the risk of hypertensive disease of pregnancy.
Park FJ, Leung CH, Poon LC, Williams PF, Rothwell SJ, Hyett JA.
Aust N Z J Obstet Gynaecol 2013; 53: 532-539.
62How feasible is expectant management of interstitial ectopic pregnancy?
Poon LC, Emmanuel E, Ross J, Johns J.
Ultrasound Obstet Gynecol 2013, Ultrasound Obstet Gynecol 2014; 43: 317-321.
63Association of placental perfusion, as assessed by magnetic resonance imaging and uterine artery Doppler ultrasound, and its relationship to pregnancy outcome.
Derwig I, Lythgoe DJ, Barker GJ, Poon L, Gowland P, Yeung R, Fernando Z, Nicolaides, KH.
Placenta 2013; 34: 885-891.
64First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell free DNA testing.
Nicolaides KH, Wright D, Poon L, Syngelaki A, Gil M.
Ultrasound Obstet Gynecol 2013; 42: 41-50.
65Second-trimester screening for trisomy 21 using prefrontal space ratio.
Chaveeva P, Agathokleous M, Poon LC, Markova D, Nicolaides KH.
Fetal Diagn Ther 2013; 34: 50-55.
66Maternal thyroid function at 11-13 weeks’ gestation in twin pregnancy.
Ashoor G, Muto O, Poon LC, Abdulla M, Nicolaides KH.
Thyroid 2013; 23: 1165-1171.
67Maternal serum cytokines at 30-33 weeks in the prediction of preeclampsia.
Mosimann B, Wagner M, Poon LC, Bansal AS, Nicolaides KH.
Prenatal Diagnosis 2013; 33: 823-830.
68Association of placental T2 relaxation times and uterine artery Doppler ultrasound measures of placental blood flow.
Derwig I, Barker GJ, Poon L, Zelaya F, Gowland P, Lythgoe DJ, Nicolaides KH.
Placenta 2013; 34: 474-479.
69Natural killer cells and their activation status in normal pregnancy.
Mosimann B, Wagner M, Shehata H, Poon LC, Ford B, Nicolaides KH, Bansal AS.
International Journal of Reproductive Medicine 2013; 2013: 906813.
70Maternal plasma cell-free fetal and maternal DNA at 11-13 weeks’ gestation: Relation to fetal and maternal characteristics and pregnancy outcomes.
Poon LC, Musci T, Song K, Syngelaki A, Nicolaides KH.
Fetal Diagn Ther 2013; 33: 215-223.
71Maternal Serum Placental Growth Factor, Pregnancy-Associated Plasma Protein-A and Free β-Human Chorionic Gonadotrophin at 30-33 Weeks in the Prediction of Pre-Eclampsia.
Lai J, Pinas A, Poon LC, Agathokleous M, Nicolaides KH.
Fetal Diagn Ther 2013; 33: 164-172.
72Meta-analysis of second-trimester markers for trisomy 21.
Agathokleous M, Chaveeva P, Poon LC, Kosinski P, Nicolaides KH.
Ultrasound Obstet Gynecol 2013; 41: 247-261.
73Maternal serum tumour necrosis factor receptor 1 (TNF-R1) at 30-33 weeks in the prediction of preeclampsia.
Mosimann B, Wagner M, Birdir C, Poon LC, Nicolaides KH.
J Matern Fetal Neonatal Med 2013; 26: 763-767.
74Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks' gestation: relation to maternal and fetal characteristics.
Ashoor G, Syngelaki A, Poon L, Rezende J, Nicolaides K.
Ultrasound Obstet Gynecol 2013; 41: 26-32.
75Maternal serum retinol-binding protein-4 at 11-13 weeks’ gestation in normal and pathological pregnancies.
Nanda S, Nikoletakis G, Markova D, Poon LC, Nicolaides KH.
Metabolism 2013; 62: 814-819.
76Maternal serum activin-A at 30-33 weeks in the prediction of preeclampsia.
Lai J, Pinas A, Syngelaki A, Poon LC, Nicolaides KH.
J Matern Fetal Neonatal Med 2013; 26: 733-737.
77Mean arterial pressure, systolic and diastolic blood pressure at 30–33 weeks in the prediction of preeclampsia.
Lai J, Poon LC, Bakalis S, Markova D, Nicolaides KH.
Fetal Diagn Ther 2013; 33: 173-181.
78Uterine artery Doppler at 30–33 weeks’ gestation in the prediction of preeclampsia.
Lai J, Poon LC, Pinas A, Bakalis S, Nicolaides KH.
Fetal Diagn Ther 2013; 33: 156-163.
79Second-trimester uterine artery Doppler in the prediction of stillbirths.
Poon LC, Volpe N, Muto B, Yu CKH, Syngelaki A, Nicolaides KH.
Fetal Diagn Ther 2013; 33: 28-35.
80Combined screening for preeclampsia and small for gestational age at 11–13 weeks.
Poon LC, Syngelaki A, Akolekar R, Lai J, Nicolaides KH.
Fetal Diagn Ther 2013; 33: 16-27.
81Competing risks model in early screening for preeclampsia by biophysical and biochemical markers.
Akolekar R, Syngelaki A, Poon LC, Wright D, Nicolaides KH.
Fetal Diagn Ther 2013; 33: 8-15.
82Maternal serum soluble endoglin (sEng) at 30-33 weeks in the prediction of preeclampsia.
Lai J, Syngelaki A, Poon LC, Nucci M, Nicolaides KH.
Fetal Diagn Ther 2013; 33: 149-155.
83A competing risks model in early screening for preeclampsia.
Wright D, Akolekar R, Syngelaki A, Poon LC, Nicolaides KH.
Fetal Diagn Ther 2012; 32: 171-178.
84Birthweight with gestation and maternal characteristics in live births and stillbirths.
Poon LC, Volpe N, Muto B, Syngelaki A, Nicolaides KH.
Fetal Diagn Ther 2012; 32: 156-165.
85C-reactive protein at 11 to 13 weeks’ gestation in spontaneous early preterm delivery.
Bakalis S, Poon LC, Vayna AM, Pafilis I, Nicolaides KH.
J Matern Fetal Neonatal Med 2012; 25: 2475-2478.
86Maternal serum ferritin at 11 to 13 weeks’ gestation in spontaneous early preterm delivery.
Beta J, Poon LC, Bakalis S, Mosimann B, Nicolaides KH.
J Matern Fetal Neonatal Med 2012; 25:1852-1855.
87Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks’ gestation: Effect of maternal and fetal factors.
Ashoor G, Poon LC, Syngelaki A, Mosimann B, Nicolaides KH.
Fetal Diagn Ther 2012; 31: 237-243.
88First trimester screening for spontaneous preterm delivery with maternal characteristics and cervical length.
Greco E, Gupta R, Syngelaki A, Poon LC, Nicolaides KH.
Fetal Diagn Ther 2012; 31: 154-161.
89Protocol for measurement of mean arterial pressure at 11-13 weeks’ gestation.
Poon LC, Zymeri NA, Zamprakou A, Syngelaki A, Nicolaides KH.
Fetal Diagn Ther 2012; 31: 42-48.
90First trimester screening for neural tube defects using AFP.
Bredaki FE, Poon LC, Birdir C, Escalante D, Nicolaides KH.
Fetal Diagn Ther 2012; 31: 109-114.
91Maternal serum resistin at 11-13 weeks’ gestation in normal and pathological pregnancies.
Nanda S, Poon LC, Muhaisen M, Acosta IC, Nicolaides KH.
Metabolism 2012; 61: 699-705.
92Large loop excision of transformation zone and cervical length in the prediction of spontaneous preterm delivery.
Poon LC, Savvas M, Zamblera D, Skyfta E, Nicolaides KH.
BJOG 2012; 119: 692-698.
93Systolic diastolic and mean arterial pressure at 11-13 weeks in the prediction of hypertensive disorders in pregnancy: a prospective screening study.
Poon LC, Kametas NA, Valencia C, Chelemen T, Nicolaides KH.
Hypertens Pregnancy 2011; 30: 93-107.
94First-trimester prediction of macrosomia.
Poon LC, Karagiannis G, Stratieva V, Syngelaki A, Nicolaides KH.
Fetal Diagn Ther 2011; 29: 139-147.
95Reference range of birth weight with gestation and first-trimester prediction of small for gestation neonates.
Poon LC, Karagiannis G, Staboulidou I, Shafiei A, Nicolaides KH.
Prenat Diagn 2011; 31: 58-65.
96Normal ranges of embryonic length, embryonic heart rate, gestational sac diameter and yolk sac diameter in early pregnancy.
Papaioannou GKI, Syngelaki A, Poon LC, Ross J, Nicolaides KH.
Fetal Diagn Ther 2010; 28: 207-219.
97Hypertensive disorders in pregnancy: Screening by biophysical and biochemical markers at 11-13 weeks.
Poon LC, Akolekar R, Lachmann R, Beta J, Nicolaides KH.
Ultrasound in Obstetrics and Gynecology 2010; 35: 662-670.
98Hypertensive disorders in pregnancy: combined screening by uterine artery Doppler, blood pressure and serum PAPP-A at 11-13 weeks.
Poon LC, Stratieva V, Piras S, Piri S, Nicolaides KH.
Prenat Diagn 2010; 30: 216-223.
99Hypertensive disorders in pregnancy: Screening by uterine artery Doppler and blood pressure at 11-13 weeks.
Poon LC, Karagiannis G, Leal A, Romero Infante X, Nicolaides KH.
Ultrasound in Obstetrics and Gynecology 2009; 34: 497-502.
100Hypertensive disorders in pregnancy: Screening by uterine artery Doppler at 11-13 weeks.
Poon LC, Staboulidou I, Maiz N, Plasencia W, Nicolaides KH.
Ultrasound in Obstetrics and Gynecology 2009; 34: 142-148.
101Maternal risk factors for hypertensive disorders in pregnancy: a multivariate approach.
Poon LC, Kametas NA, Chelemen T, Leal A, Nicolaides KH.
J Hum Hypertens 2010; 24: 104-110.
102First-trimester prediction of hypertensive disorders in pregnancy.
Poon LC, Kametas NA, Maiz N, Akolekar R, Nicolaides KH.
Hypertension 2009; 53: 812-818.
103First-trimester maternal serum matrix metalloproteinase-9 (MMP-9) and adverse pregnancy outcome.
Poon LC, Nekrasova E, Anastassopoulos P, Livanos P, Nicolaides KH.
Prenatal Diagnosis 2009; 29: 553-559.
104Maternal serum placental growth factor (plgf) at 11+0 to 13+6 weeks of gestation in small for gestational age pregnancy.
Poon LC, Zaragoza E, Akolekar R, Anagnostopoulos E, Nicolaides KH.
Prenatal Diagnosis 2008; 28: 1110-1115.
105First trimester urinary placental growth factor and development of pre-eclampsia.
Savvidou M, Akolekar R, Zaragoza E, Poon L, Nicolaides KH.
BJOG 2009; 116: 643-647.
106First-trimester maternal serum tumor necrosis factor receptor-1 (TNF-R1) and preeclampsia.
Leal AM, Poon LC, Frisova V, Veduta A, Nicolaides KH.
Ultrasound in Obstetrics and Gynecology 2009; 33: 135-141.
107Maternal serum placental growth factor (plgf) at 11+0 to 13+6 weeks of gestation in hypertensive disorders of pregnancy.
Akolekar R, Zaragoza E, Poon LC, Pepes S, Nicolaides KH.
Ultrasound in Obstetrics and Gynecology 2008; 32: 732-739.
108Maternal serum placental growth factor (plgf) at 11+0-13+6 weeks in chromosomally abnormal pregnancies.
Zaragoza E, Akolekar R, Poon LC, Pepes S, Nicolaides KH.
Ultrasound in Obstetrics and Gynecology 2009; 33: 382-386.
109First-trimester maternal serum PAPP-A and preeclampsia.
Poon LC, Maiz N, Valencia C, Plasencia W, Nicolaides KH.
Ultrasound in Obstetrics and Gynecology 2009; 33: 23-33.
110Maternal serum ADAM12 (A Disintegrin And Metalloprotease) in chromosomally abnormal pregnancies at 11+0-13+6 weeks.
Poon LC, Chelemen T, Minekawa R, Frisova V, Nicolaides KH.
American Journal Obstetrics and Gynecology 2009; 200: 508.e1-6.
111First trimester maternal serum A Disintegrin And Metalloprotease 12 and adverse pregnancy outcome.
Poon LC, Chelemen T, Granvillano O, Pandeva I, Nicolaides KH.
Obstetric Gynecol 2008; 112: 1082-1090.
112Fetal Medicine Foundation Prolonged Pregnancy Group. Cervical length and maternal factors in expectantly managed prolonged pregnancy: prediction of onset of labor and mode of delivery.
Rao A, Celik E, Poggi S, Poon L, Nicolaides KH;
Ultrasound Obstet Gynecol 2008; 32: 646-651.
113Prediction of preeclampsia by a combination of maternal history, uterine artery doppler and mean arterial pressure.
Onwudiwe N, Yu CKH, Poon LC, Spiliopoulos I, Nicolaides KH.
Ultrasound Obstet Gynecol 2008; 32: 877-883.
114Uterine artery Doppler at 11+0-13+6 weeks and 21+0-24+6 weeks in the prediction of pre-eclampsia.
Plasencia W, Maiz N, Poon L, Yu C, Nicolaides KH.
Ultrasound Obstet Gynecol 2008; 32: 138-146.
115Inter-arm blood pressure differences in pregnant women.
Poon LC, Kametas N, Strobl I, Pachoumi C, Nicolaides KH.
BJOG 2008; 115: 1122-1130.
116Mean arterial pressure at 11+0-13+6 weeks in the prediction of pre-eclampsia.
Poon LC, Kametas N, Pandeva IV, Valencia CM, Nicolaides KH.
Hypertension 2008; 51: 1027-1033.
117Urine albumin concentration and albumin-to-creatinine ratio at 11+0-13+6 weeks in the prediction of pre-eclampsia.
Poon LC, Kametas N, Bonino S, Vercellotti E, Nicolaides KH.
BJOG 2008; 115: 866-873.
118Blood pressure levels correlate with intra-individual variability using an automated device in early pregnancy.
Poon LC, Kametas N, Valencia CM, Pandeva IV, Nicolaides KH.
J Hum Hypertens 2008; 22: 438-440.
119Tetralogy of Fallot in the fetus in the current era.
Poon LC, Huggon I, Zidere V and Allan LD.
Ultrasound Obstet Gynecol 2007; 29: 625-627.
120Audit of the effectiveness of cervical preparation with Dilapan prior to late second trimester (20-24 weeks) surgical termination of pregnancy.
Poon LC, Parsons J.
BJOG 2007; 114: 485-488.
2017-08-14T11:15:42+00:00